4-Anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5090-5102

  Spicer, Julie A ^a   Rewcastle, Gordon W ^a   Kaufman, Michael D ^b   Black, Shannon L ^a   Plummer, Mark S ^b   Denny, William A ^a   Quin III, John ^b   Shahripour, Aurash B ^b   Barrett, Stephen D ^b   Whitehead, Christopher E ^b   Milbank, Jared B J ^b   Ohren, Jeffrey F ^b   Gowan, Richard C ^b   Omer, Charles ^b   Camp, Heidi S ^b   Esmaeil, Nadia ^b   Moore, Kelley ^b   Sebolt Leopold, Judith S ^b   Pryzbranowski, Sally ^b   Merriman, Ronald L ^b   Ortwine, Daniel F ^b   Warmus, Joseph S ^b   Flamme, Cathlin M ^b   Pavlovsky, Alexander G ^b   Tecle, Haile ^b   more..

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (2 FLUORO 4 IODOANILINO) 1 METHYL 6 OXO 1,6 DIHYDRO 3 PYRIDINECARBOXAMIDE; 4 ANILINO 5 CARBOXAMIDO 2 PYRIDONE DERIVATIVE; AMIDE; DIPYRONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NITROGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; COLON CARCINOMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; MEASUREMENT; MOUSE; NONHUMAN; TREATMENT RESPONSE;

AMIDES; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PYRIDONES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35348843516     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0704548     Document Type: Article

References (34)

1. Ahn, N. G.; Seger, R.; Bratlien, R. L.; Diltz, C. D.; Tonks, N. K.; Krebs, E. G. Multiple components in an epidermal growth factor-stimulated protein kinase cascade: in vitro activation of a myelin basic protein/microtuble-associated protein 2 kinase. J. Biol. Chem. 1991, 266, 4220-4227.
2. Schaeffer, H. J.; Weber, M. J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 1999, 19, 2435-2444.
3. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H.; Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22, 153-83.
4. Zheng, C. F.; Guan, K. L. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem. 1993, 268, 11435-11439.
5. Thompson, N.; Lyons, J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 2005, 5, 350-356.
6. Wallace, E. M.; Lyssikatos, J. P.; Yeh, T.; Winkler, J. D.; Koch, K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Topics Med. Chem. 2005, 5, 215-229.
7. Wallace, E. M.; Lyssikatos, J.; Blake, J. F.; Seo, J.; Yang, H. W.; Yeh, T. C.; Perrier, M.; Jarski, H.; Marsh, V.; Poch, G.; Livingston, M. G.; Otten, J.; Hingorani, G.; Woessner, R.; Lee, P.; Winkler, J.; Koch, K. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones. J. Med. Chem. 2006, 49, 441-444.
8. El, Abdellaoui, H.; Varaprasad, C. V. N. S.; Barawkar, D.; Chakravarty, S.; Maderna, A.; Tam, R.; Chen, H.; Allan, M.; Wu, J. Z.; Appleby, T.; Yan, S.; Zhang, W.; Lang, S.; Yao, N.; Hamatake, R.; Hong, Z. Identification of isothiazole-4-carboxamidine derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5561-5566.
9. (a) Tecle, H. The development of rion-ATP competitive MEK inhibitors as potential anticancer drugs. Presented at the 29th American Chemical Society Medicinal Chemistry Symposium, Madison, WI, June 27-July 1, 2004.
10. (b) Kaufman, M. D.; Barrett, S. D.; Flamme, C. M.; Warmus, J.; Smith, Y. D.; Cheriyan, M.; Zhang, L.; Tecle, H.; Sebolt-Leopold, J.; Valik, H.; Gowan, R.; Van Becelaere, K.; Merriman, R.; Przybranowski, S.; Ohren, J.; Whitehead, C.; Leopold, W. R.; Dobrusin, E.; Bridges, A. Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. Proc. Am. Assoc. Cancer Res. 2004, 45, Abstract 2477.
11. (a) Yeh, T. C.; Marsh, V.; Bernat, B. A.; Ballard, J.; Colwell, H.; Evans, R. J.; Parry, J.; Smith, D.; Brandhuber, B. J.; Gross, S.; Marlow, A.; Hurley, B.; Lyssikatos, J.; Lee, P. A.; Winkler, J. D.; Koch, K.; Wallace, E. Biological characterization of ARRY-142886 (AZD6244) a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 2007, 13, 1576-1583.
12. (b) Chow, L. Q. M.; Eckhardt, S. G.; Reid J.; Molina, J.; Hanson, L.; Piens, J.; Hariharan, S.; Basche, M.; Gore, L.; Diab, S.; OBryant, C.; Grolnic, S.; Hippert, B.; Doyle, M. P.; Maloney, L.; Gordon, G.; Brown, S.; Litwiler, K.; Poch, G.; Adjei, A. A. A first in human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor, ARRY-142886 (AZD6244), in patients with advanced solid malignancies [abstract C162]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, November 14-18, 2005; American Association for Cancer Research: Philadelphia, PA.
13. Sebolt-Leopold, J. S.; Dudley, D. T.; Herrera, R.; Van Becelaere, K.; Wiland, A.; Gowan, R. C.; Tecle, H.; Barrett, S. D.; Bridges, A.; Przybranowski, S.; Leopold, W. R.; Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 1999, 5, 810-816.
14. Allen, L. F.; Sebolt-Leopold, J.; Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 2003, 30 (5 Suppl 16), 105-116.
15. Sebolt-Leopold, J. S. MEK inhibitors: A therapeutic approach to targeting the ras-MAP kinase pathway in tumors. Curr. Pharm. Des. 2004, 10, 1907-1914.
16. Sebolt-Leopold, J. S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev. Cancer 2004, 4, 937-94.
17. Rinehart, J.; Adjei, A. A.; LoRusso, P. M.; Waterhouse, D.; Hecht, J. R.; Natale, R. B.; Hamid, O.; Varterasian, M.; Asbury, P.; Kaldjian, E. R.; Gulyas, S.; Mitchell, D. Y.; Herrera, R.; Sebolt-Leopold, J. S.; Meyer, M. B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon and pancreatic cancer. J. Clin. Oncol. 2004, 22, 4456-4462.
18. LoRusso, P. M.; Adjei, A. A.; Varterasian, M.; Gadgeel, S.; Reid, J.; Mitchell, D. Y.; Hanson, L.; DeLuca, P.; Bruzek, L.; Piens, J.; Asbury, P.; Van Becelaere, K.; Herrera, R.; Sebolt-Leopold, J.; Meyer, M. B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 5281-5293.
19. Barrett, S. D.; Biwersi, C.; Kaufman, M.; Tecle, H.; Warmus, J. S. Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. WO 2002/06213 A2, July 12, 2001.
20. Ohren, J. F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J. S.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel non-competitive kinase inhibition. Nature Struc. Mol. Biol. 2004, 11, 1192-1197.
21. Chen, H.; Delaney, A. M.; Dudley, D. T.; Hasemann, C. A., Jr.; Kuffa, P.; McConnell, P. C.; Ohren, J. F.; Pavlovsky, A. G.; Tecle, H.; Whitehead, C. E.; Yan, C.; Zhang, E. Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and procedures of use thereof. WO 2003/054180 A1, December 9, 2002.
22. Whitehead, C. E.; Ohren, J. F.; Barrett, S.; Warmus, J.; et al. Structure-based drug design and 3D QSAR of second generation MEK1 inhibitors. Manuscript in preparation.
23. Zhu, M.; Qui, Z.; Hiel, G. P.; Sieberth, S. M. Photocycloaddition of four-carbon-tethered pyridones. Intramolecular hydrogen bonding and facilitated amide hydrolysis by a proximal secondary alcohol. J. Org. Chem. 2002, 67, 3487-3493.
24. Mekheimer, R. A. Fused quinoline heterocycles I. First example of the 2,4-diazido-quinoline-3-carbonitrile and 1-aryl-1,5-dihydro-1,2,3,4,5,6- hexaazaacephenanthrylene ring systems. J. Chem. Soc., Perkin Trans. 1 1999, 2183-2188.
25. Minato, M.; Yamamoto, K.; Tsuji, J. Osmium tetraoxide catalysed vicinal hydroxylation of higher olefins by using hexacyanoferrate-(III) ion as a cooxidant. J. Org. Chem. 1990, 55, 766-768.
26. Black, S. L.; Kaufman, M. D.; Ortwine, D. F.; Plummer, M. S.; Quin, J., III; Rewcastle, G. W.; Shahripour, A. B.; Spicer, J. A.; Whitehead, C. E. 5-Substituted-4-(substituted phenyl)amino-2-pyridone derivatives for use as MEK inhibitors. WO 2005/000818 A1 (Pfizer), June 18, 2004.
27. Marlow, A. L.; Wallace, E.; Seo, J.; Lyssikatos, J.P.; Yang, H. W.; Blake, J. Heterocyclic inhibitors of MEK and methods of use thereof. WO 2005/051301 A2 (Array BioPharma), November 18, 2004.
28. Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Illinois Institute of Technology. Use of the Advanced Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38.
29. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
30. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.
31. Collaborative, Computational, Project, Number, 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994, D50, 760-763.
32. Albert, A.; Barlin, G. B. Triazanaphthalenes. II. Covalent hydration in 1,4,6-triaza-naphthalenes. J. Chem. Soc. 1963, 5156-5166.
33. Bushweller, J. H.; Bartlett, P. A. Sulfoxide analogs of dihydro- and tetrahydroprephenate as inhibitors of prephenate dehydratase. J. Org. Chem. 1989, 54, 2404-2409.
34. Corey, E. J.; Venkateswarlu, A. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.